JNJ News

Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S. medicines domestically and add thousands of jobs.

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.

Goldman Sachs upgraded Johnson & Johnson (JNJ) from Neutral to Buy, citing underappreciated Innovative Medicine business and upcoming product cycles.

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

Johnson & Johnson reports long-term efficacy and steroid-sparing benefits of nipocalimab in antibody-positive generalized myasthenia gravis.

Shares of the Health Care Select Sector SPDR Fund are trading lower by 8.6% over the past week. Tariff announcements from President Donald Trump last week spooked investors and have dragged major sectors.

Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients with no new safety concerns.

Johnson & Johnson Inc. (NYSE: JNJ) shares are trading lower Tuesday after a U.S. bankruptcy court in Texas rejected subsidiary Red River Talc's request to approve its prepackaged bankruptcy plan.

Johnson & Johnson will fight talc lawsuits in court after its subsidiary's bankruptcy plan was denied, reversing $7 billion in legal reserves.

Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating superiority over Stelara in key endpoints.

Johnson & Johnson has announced a $55 billion investment in the U.S. over the next four years. This move will boost American manufacturing, research, and development, creating high-tech jobs and expanding facilities.

JNJ stock hits Golden Cross, signaling potential long-term upside. Latest breakthrough in lung cancer treatment could provide additional catalyst.

Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction.

Nanobiotix amended its $2.7 billion licensing deal with Johnson & Johnson, reducing costs while retaining key milestone payments. The update extends its cash runway to mid-2026.

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.

Janssen has sued Samsung Bioepis, alleging it violated a settlement agreement by authorizing an unauthorized Stelara® biosimilar, potentially harming market competition.